CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for IVERIC bio Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

IVERIC bio Inc
8 SYLVAN WAY, Suite 2372
Phone: (609) 474-6755p:609 474-6755 PARSIPPANY, NJ  07054  United States Fax: (302) 636-5454f:302 636-5454
This company was Merged or Acquired on 7/11/2023.
This company ceased filing statements with the SEC on 7/21/2023.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
IVERIC bio, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of treatments for retinal diseases with unmet medical needs. Its lead asset is its clinical-stage product candidate, avacincaptad pegol, which is also referred to as ACP or Zimura, a complement C5 inhibitor. Zimura is targeting diseases including geographic atrophy (GA), intermediate age-related macular degeneration (AMD), and autosomal recessive Stargardt disease (STGD1). In addition to ACP, the Company is also developing its preclinical product candidate, IC-500, a high temperature requirement A serine peptidase 1 protein (HtrA1) inhibitor for GA secondary to AMD and potentially other age-related retinal diseases. Its portfolio also includes several ongoing gene therapy research programs, each of which uses adeno-associated virus (AAV) for gene delivery. These AAV mediated gene therapy programs are targeting the orphan inherited retinal diseases (IRDs).
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202312/31/2022YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Adrienne L.Graves 69 5/1/2021 12/12/2018
President, Director Pravin U.Dugel 59 1/1/2023 3/1/2020
Chief Executive Officer, Director Glenn P.Sblendorio 67 5/1/2021 7/1/2013
8 additional Officers and Directors records available in full report.

Business Names
Business Name
Inception 4, Inc.
IVERIC bio Europe Limited
IVERIC bio Gene Therapy LLC
Orion Ophthalmology LLC

General Information
Number of Employees: 74 (As of 1/31/2023)
Outstanding Shares: 137,976,851 (As of 5/19/2023)
Shareholders: 96
Stock Exchange: NASD
Federal Tax Id: 208185347
Fax Number: (302) 636-5454


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, November 11, 2024